{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T07:55:29Z","timestamp":1768031729161,"version":"3.49.0"},"reference-count":23,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&T"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.5582\/ddt.2025.01096","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T22:07:54Z","timestamp":1765404474000},"page":"389-394","source":"Crossref","is-referenced-by-count":0,"title":["Disproportionality and time-to-onset analyses of drug-induced weight gain using the Japanese Adverse Drug Event Report database"],"prefix":"10.5582","volume":"19","author":[{"given":"Naohito","family":"Ide","sequence":"first","affiliation":[{"name":"Department of Practical Pharmacy, Nihon Pharmaceutical University, Saitama, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rika","family":"Shibata","sequence":"additional","affiliation":[{"name":"Department of Practical Pharmacy, Nihon Pharmaceutical University, Saitama, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ichi","family":"Sako","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Nihon Pharmaceutical University, Saitama, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoji","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Nihon Pharmaceutical University, Saitama, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Jallon P, Picard F. Bodyweight gain and anticonvulsants. Drug Saf. 2001; 24:969-978.","DOI":"10.2165\/00002018-200124130-00004"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Anekwe CV, Ahn YJ, Baj a j SS, Stanford FC. Pharmacotherapy causing weight gain and metabolic alteration in those with obesity and obesity-related conditions: a review. Ann N Y Acad Sci. 2024; 1533:145-155.","DOI":"10.1111\/nyas.15112"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Ide N, Sako KI, Takigawa M, Tanaka H. Risk and time-to-onset of acute kidney injury with vancomycin plus piperacillin-tazobactam combination: analysis using JADER. In Vivo. 2024; 38:1436-1442.","DOI":"10.21873\/invivo.13586"},{"key":"4","unstructured":"4. Kato H, Koseki T, Kondo M. Occurrence of somnolence and respiratory depression induced by pregabalin and mirogabalin use and the influence of opioid treatment using the Japanese adverse drug event report database. Pharmazie. 2024; 79:169-172."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Liu Q, Wang Y, Hu P, He P. Abortion adverse events associated with adalimumab, etanercept, ustekinumab, and dupilumab during pregnancy: A pharmacovigilance study based on FDA adverse event reporting system. Drug Discov Ther. 2025; 19:160-173.","DOI":"10.5582\/ddt.2025.01043"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Yang L, Zhang W, Shen X, Liu M, Wu M, Xiao D. Fosfomycin-associated adverse events : A disproportionality analysis of the FDA Adverse Event Reporting System. Drug Discov Ther. 2025; 19:1-9.","DOI":"10.5582\/ddt.2025.01008"},{"key":"7","unstructured":"7. Ahmed NJ, Alshehri AM, Almalki ZS, Alahmari A. Drug-induced weight gain in the last 10 years: a descriptive study. Pharmazie. 2022; 77:299-301."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Van Puijenbroek EP, Bate A, Leufkens HGM, Lindquist M, Orre R, Egberts ACG. A comparison of measures of disproportionality for signal detection is spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002; 11:3-10.","DOI":"10.1002\/pds.668"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Katsuhara Y, Ogawa T. Acute renal failure, ketoacidosis, and urogenital tract infections with SGLT2 inhibitors: signal detection using a Japanese spontaneous reporting database. Clin Drug Investig. 2020; 40:645-652.","DOI":"10.1007\/s40261-020-00925-3"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Asano H, Noguchi Y, Kimura M, Usami E, Yoshimura T. Pituitary-related adverse events and onset patterns caused by immune checkpoint inhibitors: analysis using the Japanese adverse drug event report database. Medicina (Kaunas). 2023; 59:1963.","DOI":"10.3390\/medicina59111963"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Sauzet O, Carvajal A, Escudero A, Molokhia M, Cornelius VR. Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data. Drug Saf. 2013; 36:995-1006.","DOI":"10.1007\/s40264-013-0061-7"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Wu CS, Lin YJ, Liu SK. Benzodiazepine use among patients with schizophrenia in Taiwan: a nationwide population-based survey. Psychiatr Serv. 2011; 62:908-914.","DOI":"10.1176\/ps.62.8.pss6208_0908"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Muscogiuri G, Verde L, Vetrani C, Barrea L, Savastano S, Colao A. Obesity: a gender-view. J Endocrinol Invest. 2024; 47:299-306.","DOI":"10.1007\/s40618-023-02196-z"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Mukai R, Hasegawa S, Umetsu R, Nakao S, Shimada K, Uranishi H, Masuta M, Suzuki H, Nishibata Y, Nakamura M. Evaluation of pregabalin-induced adverse events related to falls using the FDA adverse event reporting system and Japanese adverse drug event report databases. J Clin Pharm Ther. 2019; 44:285-291.","DOI":"10.1111\/jcpt.12790"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Cabrera J, Emir B, Dills D, Murphy TK, Whalen E, Clair A. Characterizing and understanding body weight patterns in patients treated with pregabalin. Curr Med Res Opin. 2012; 28:1027-1037.","DOI":"10.1185\/03007995.2012.684044"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Ikeda H, Yonemochi N, Ardianto C, Yang L, Kamei J. Pregabalin increases food intake through dopaminergic systems in the hypothalamus. Brain Res. 2018; 1701:219-226.","DOI":"10.1016\/j.brainres.2018.09.026"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel \u03b12\u2013\u03b4 (alpha2\u2013delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007; 73:137-150.","DOI":"10.1016\/j.eplepsyres.2006.09.008"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Micheva KD, Taylor CP, Smith SJ. Pregabalin reduces the release of synaptic vesicles from cultured hippocampal neurons. Mol Pharmacol. 2006; 70:467-476.","DOI":"10.1124\/mol.106.023309"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Grajales D, Ferreira V, Valverde \u00c1M. Second-generation antipsychotics and dysregulation of glucose metabolism: beyond weight gain. Cells. 2019; 8:1336.","DOI":"10.3390\/cells8111336"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Smith SR, Jonge LD, Volaufova J, Li Y, Xie H, Bray GA. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial. Metabolism. 2005; 54:24-32.","DOI":"10.1016\/j.metabol.2004.07.008"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Ko KD, Kim KK, Lee KR. Does weight gain associated with thiazolidinedione use negatively affect cardiometabolic health? J Obes Metab Syndr. 2017; 26:102-106.","DOI":"10.7570\/jomes.2017.26.2.102"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Zanchi A, Chiolero A, Maillard M, Nussberger J, Brunner HR, Michel Burnier M. Effects of the peroxisomal proliferator-activated receptor-\u03b3 agonist pioglitazone on renal and hormonal responses to salt in healthy men. J Clin Endocrinol Metab. 2004; 89:1140-1145.","DOI":"10.1210\/jc.2003-031526"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Safari MAM, Masseran N, Majid MHA, Tajuddin RRM. Robust estimation of the three parameter weibull distribution for addressing outliers in reliability analysis. Sci Rep. 2025; 15:11516.","DOI":"10.1038\/s41598-025-96043-1"}],"container-title":["Drug Discoveries & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/19\/6\/19_2025.01096\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T04:19:59Z","timestamp":1768018799000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/19\/6\/19_2025.01096\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2025.01096","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]},"article-number":"2025.01096"}}